Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016; New Report Launched

Growth/Differentiation Factor 8 (Myostatin or GDF-8) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The report GrowthDifferentiation Factor 8 – Pipeline Review, H1 2016, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth/Differentiation Factor 8 (Myostatin or GDF-8) Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFβ) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 7 respectively.

Furthermore, this report also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
• The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics and enlists all their major and minor projects
• The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF-8) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

For more information Visit at: http://mrr.cm/JRd

Related Reports;

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JRP

C5a Anaphylatoxin Chemotactic Receptor 1 (C5a Anaphylatoxin Chemotactic Receptor or C5a-R or CD88 or C5AR1) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JRW

Apolipoprotein E (ApoE) - Pipeline Review, H1 2016 - Visit at - http://mrr.cm/JRm